| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Eun Jung Lee, David Hernán Aguirre-Padilla, Anton Fomenko, Grishma Pawar, Minesh Kapadia, Jimmy George, Andres M Lozano, Clement Hamani, Lorraine V Kalia, Suneil K Kali. Reduction of alpha synuclein oligomers in preclinical models of Parkinson's disease by electrical stimulation in vitro and deep brain stimulation in vivo. Brain stimulation. 2024-02-11. PMID:38342364. |
accumulation and oligomerization of the protein alpha-synuclein (α-syn) are implicated in the loss of dopaminergic neurons in the substantia nigra in pd, making α-syn a potential therapeutic target for disease modification. |
2024-02-11 |
2024-02-14 |
Not clear |
| Fabio Casciano, Enrico Zauli, Claudio Celeghini, Lorenzo Caruso, Arianna Gonelli, Giorgio Zauli, Angela Pignatell. Retinal Alterations Predict Early Prodromal Signs of Neurodegenerative Disease. International journal of molecular sciences. vol 25. issue 3. 2024-02-10. PMID:38338966. |
in parkinson's disease, α-synuclein deposition in the retinal cells, as well as in dopaminergic neurons of the substantia nigra, alters the visual cortex and retinal function, resulting in modifications to the visual field. |
2024-02-10 |
2024-02-12 |
Not clear |
| Takeya Kitta, Teruyuki Ogawa, Sadako Kuno, Hidehiro Kakizaki, Naoki Yoshimur. Review: Lower urinary tract dysfunction in animal models of Parkinson's disease (PD): Translational aspects for the treatment of PD patients with overactive bladder. International review of neurobiology. vol 174. 2024-02-10. PMID:38341230. |
although the loss of dopaminergic neurons in the substantia nigra and consequent motor symptoms are the hallmarks of parkinson's disease (pd), several non-motor symptoms may appear prior to these typical motor symptoms. |
2024-02-10 |
2024-02-14 |
Not clear |
| Shani Blumenreich, Tamar Nehushtan, Meital Kupervaser, Tali Shalit, Alexandra Gabashvili, Tammar Joseph, Ivan Milenkovic, John Hardy, Anthony H Futerma. Large-scale proteomics analysis of five brain regions from Parkinson's disease patients with a GBA1 mutation. NPJ Parkinson's disease. vol 10. issue 1. 2024-02-08. PMID:38331996. |
two proteins were differentially-expressed in all five brain regions whereas significant differences were detected between the brain regions, with changes consistent with loss of dopaminergic signaling in the substantia nigra, and activation of a number of pathways in the cingulate gyrus, including ceramide synthesis. |
2024-02-08 |
2024-02-11 |
Not clear |
| Qiuyu Lv, Xuanyi Wang, Pan Lin, Xiang Wan. Neuromelanin-sensitive magnetic resonance imaging in the study of mental disorder: A systematic review. Psychiatry research. Neuroimaging. vol 339. 2024-02-07. PMID:38325165. |
recent research suggests that neuromelanin-sensitive magnetic resonance imaging (nm-mri) techniques may overcome this limitation by enabling the non-invasive imaging of the substantia nigra (sn)/ ventral tegmental area (vta) dopaminergic and locus coeruleus (lc) noradrenergic systems. |
2024-02-07 |
2024-02-10 |
Not clear |
| Larissa Pereira Dantas da Silva, Erika da Cruz Guedes, Isabel Cristina Oliveira Fernandes, Lucas Aleixo Leal Pedroza, Gustavo José da Silva Pereira, Priscila Guber. Exploring Caenorhabditis elegans as Parkinson's Disease Model: Neurotoxins and Genetic Implications. Neurotoxicity research. vol 42. issue 1. 2024-02-06. PMID:38319410. |
patients with pd have a loss of dopaminergic neurons in the substantia nigra of the basal ganglia, which controls voluntary movements, causing a motor impairment as a result of dopaminergic signaling impairment. |
2024-02-06 |
2024-02-09 |
human |
| Rongsha Chen, Ke Li, Yinying Wang, Liyun Song, Ruohua Wang, Wenhui Fan, Ninghui Zhao, Wei Zou, Zhongshan Yang, Jinyuan Ya. Valeric acid reduction by chitosan oligosaccharide induces autophagy in a Parkinson's disease mouse model. Journal of drug targeting. 2024-02-05. PMID:38315456. |
the present study demonstrated that cos increased dopaminergic neurons in the substantia nigra (sn) and ameliorated dyskinesia in a pd mouse model. |
2024-02-05 |
2024-02-09 |
mouse |
| Kei-Ichi Ishikawa, Ayami Okuzumi, Hiroyo Yoshino, Nobutaka Hattori, Wado Akamats. Generation of hiPSCs (JUCGRMi003-A) from a patient with Parkinson's disease with PARK2 mutation. Stem cell research. vol 76. 2024-02-03. PMID:38309147. |
park2 is the most common autosomal recessive form of parkinson's disease and is caused by mutations in parkin that result in early-onset loss of dopaminergic neurons in the substantia nigra. |
2024-02-03 |
2024-02-06 |
Not clear |
| Chong-Lei Fu, Bo-Cheng Dong, Xi Jiang, Dan Li, Jun Ya. A cell therapy approach based on iPSC-derived midbrain organoids for the restoration of motor function in a Parkinson's disease mouse model. Heliyon. vol 10. issue 2. 2024-01-31. PMID:38293351. |
parkinson's disease (pd) is a neurodegenerative disease characterized by the degeneration of dopaminergic (da) neurons in the substantia nigra and loss of da transmission in the striatum, thus making cell transplantation an effective treatment strategy. |
2024-01-31 |
2024-02-02 |
mouse |
| Ana Perez-Villalba, María Salomé Sirerol-Piquer, Raúl Soriano-Cantón, Virginia Folgado, Azucena Pérez-Cañamás, Martina Kirstein, Isabel Fariñas, Francisco Pérez-Sánche. Dopaminergic neuron loss in mice due to increased levels of wild-type human α-Synuclein only takes place under conditions of accelerated aging. Scientific reports. vol 14. issue 1. 2024-01-30. PMID:38291230. |
these motor disturbances correlate with reduced dopamine (da) levels, increased da turnover, synaptic terminal loss, and notably, the depletion of dopaminergic neurons in the substantia nigra and noradrenergic neurons in the locus coeruleus. |
2024-01-30 |
2024-02-02 |
mouse |
| Vasanthi Chinraj, Ramakkamma Aishwarya Reddy, Jubie Selvaraj, Raman Sureshkuma. Design, Synthesis and In Vitro Evaluation of Levodopa Stearic Acid Hydrazide Conjugate for the Management of Parkinson's DiseaseNovel Conjugate for Parkinson's Disease. Drug research. 2024-01-29. PMID:38286420. |
the pathological identification for parkinson's disease is loss of dopaminergic neurons in substantia nigra region of the brain that in turn leads to dopamine deficiency that affects the body's normal physiological and neurological disorder. |
2024-01-29 |
2024-02-01 |
Not clear |
| b' Simone D\'Angiolini, Maria Lui, Emanuela Mazzon, Marco Calabr\\xc3\\xb. Network Analysis Performed on Transcriptomes of Parkinson\'s Disease Patients Reveals Dysfunction in Protein Translation. International journal of molecular sciences. vol 25. issue 2. 2024-01-27. PMID:38279299.' |
parkinson's disease (pd) is a prevalent neurodegenerative disorder characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra region of the brain. |
2024-01-27 |
2024-01-29 |
Not clear |
| Bin Hong, Yosuke Ohtake, Takahide Itokazu, Toshihide Yamashit. Glial senescence enhances α-synuclein pathology owing to its insufficient clearance caused by autophagy dysfunction. Cell death discovery. vol 10. issue 1. 2024-01-25. PMID:38272865. |
parkinson's disease (pd) is characterized by the pathological accumulation of α-synuclein (α-syn) and loss of dopaminergic neurons in the substantia nigra. |
2024-01-25 |
2024-01-28 |
mouse |
| Junming Huang, Bowen Li, Huangwei Wei, Chengxin Li, Chao Liu, Hua Mi, Shaohua Che. Integrative analysis of gene expression profiles of substantia nigra identifies potential diagnosis biomarkers in Parkinson's disease. Scientific reports. vol 14. issue 1. 2024-01-25. PMID:38272954. |
parkinson's disease (pd) is a progressive neurodegenerative disease whose etiology is attributed to development of lewy bodies and degeneration of dopaminergic neurons in the substantia nigra (sn). |
2024-01-25 |
2024-01-28 |
human |
| Yea-Hyun Leem, Jin-Sun Park, Jung-Eun Park, Do-Yeon Kim, Hee-Sun Ki. Creatine supplementation with exercise reduces α-synuclein oligomerization and necroptosis in Parkinson's disease mouse model. The Journal of nutritional biochemistry. 2024-01-23. PMID:38262563. |
we found that 2% creatine supplementation and/or exercise intervention for 4 weeks elicited neurobehavioral recovery and neuroprotective effects regarding dopaminergic cell loss in mptp-treated mice; this effect implies functional preservation of dopaminergic cells in the substantia nigra, as reflected by tyrosine hydroxylase expression recovery. |
2024-01-23 |
2024-01-26 |
mouse |
| Ignacio Serrano-Martínez, Marta Pedreño, Julia Castillo-González, Viviane Ferraz-de-Paula, Pablo Vargas-Rodríguez, Irene Forte-Lago, Marta Caro, Jenny Campos-Salinas, Javier Villadiego, Pablo Peñalver, Juan Carlos Morales, Mario Delgado, Elena González-Re. Cortistatin as a Novel Multimodal Therapy for the Treatment of Parkinson's Disease. International journal of molecular sciences. vol 25. issue 2. 2024-01-23. PMID:38255772. |
we observed that treatment with cortistatin mitigated the mptp-induced loss of dopaminergic neurons in the substantia nigra and their connections to the striatum. |
2024-01-23 |
2024-01-25 |
mouse |
| Michele Salemi, Maria Ravo, Giuseppe Lanza, Francesca A Schillaci, Giovanna Maria Ventola, Giovanna Marchese, Maria Grazia Salluzzo, Graziella Cappelletti, Raffaele Ferr. Gene Expression Profiling of Post Mortem Midbrain of Parkinson's Disease Patients and Healthy Controls. International journal of molecular sciences. vol 25. issue 2. 2024-01-23. PMID:38255780. |
parkinson's disease (pd) stands as the most prevalent degenerative movement disorder, marked by the degeneration of dopaminergic neurons in the substantia nigra of the midbrain. |
2024-01-23 |
2024-01-25 |
Not clear |
| Abdeslam Chagraoui, Youssef Anouar, Philippe De Deurwaerdere, Hugo R Aria. To what extent may aminochrome increase the vulnerability of dopaminergic neurons in the context of Parkinson's disease. The international journal of biochemistry & cell biology. 2024-01-21. PMID:38246261. |
parkinson's disease (pd) is a neurodegenerative disorder that progresses over time and is characterized by preferential reduction of dopaminergic neurons in the substantia nigra. |
2024-01-21 |
2024-01-24 |
Not clear |
| Si Huang, Yong-Jiang Li, Jun-Yong Wu, Xin-Yan Hao, Wen-Jie Xu, Yu-Chen Tang, Min Zhou, Jichun Zhang, Shilin Luo, Da-Xiong Xian. Biomimetic nanodecoys deliver cholesterol-modified heteroduplex oligonucleotide to target dopaminergic neurons for the treatment of Parkinson's disease. Acta biomaterialia. 2024-01-20. PMID:38244661. |
parkinson's disease (pd) is the second most common neurodegenerative disorder characterized by the accumulation of α-synuclein (α-syn) aggregates called lewy bodies leading to the gradual loss of dopaminergic (da) neurons in the substantia nigra. |
2024-01-20 |
2024-01-23 |
Not clear |
| Tianyu Meng, Yufei Zhang, Jing Huang, Vijay Pandey, Shoupeng Fu, Shaohua M. Rubusoside mitigates neuroinflammation and cellular apoptosis in Parkinson's disease, and alters gut microbiota and metabolite composition. Phytomedicine : international journal of phytotherapy and phytopharmacology. vol 124. 2024-01-18. PMID:38237261. |
parkinson's disease (pd) is a neurodegenerative condition characterized by the progressive loss of dopaminergic neurons within the substantia nigra. |
2024-01-18 |
2024-01-21 |
Not clear |